Lenograstim

Lenograstim
INN
Drug class
Routes of administration	Injection
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Prescription only
CAS Number	143011-72-7
PubChem
DrugBank
ChemSpider
KEGG

Lenograstim is a pharmaceutical drug used primarily for the stimulation of bone marrow to produce white blood cells. It is a form of human granulocyte colony-stimulating factor (G-CSF), which is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.

Medical Uses[edit]

Lenograstim is used to increase white blood cell counts in patients undergoing chemotherapy, which often decreases levels significantly, leading to neutropenia. It is also used in the mobilization of hematopoietic stem cells in patients and donors prior to stem cell transplantation.

Mechanism of Action[edit]

Lenograstim acts by binding to G-CSF receptors on the surface of hematopoietic stem cells. This interaction stimulates the proliferation, differentiation, and survival of cells in the neutrophilic granulocyte lineage. It also activates mature neutrophils.

Pharmacokinetics[edit]

The pharmacokinetics of lenograstim involve rapid absorption and elimination when administered via injection. The drug is primarily metabolized in the kidney and liver, and its elimination half-life is relatively short.

Side Effects[edit]

Common side effects of lenograstim include bone pain, headache, nausea, and fatigue. More severe side effects may include splenic rupture, acute respiratory distress syndrome, and allergic reactions.

Regulatory Status[edit]

Lenograstim is approved for use in many countries, including those in the European Union under the trade name Granocyte. It is classified as a prescription medication and is administered under the supervision of a healthcare provider.